The SARS-CoV-2 Rapid Antibody Test is a reliable, rapid chromatographic immunoassay intended for qualitative detection of antibodies (IgM and IgG) to SARS-CoV-2 in human serum, plasma or whole blood.
The SARS-CoV-2 Rapid Antibody Test is intended for the use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection. This rapid lateral flow test is intended for professional use in laboratory and near patient-testing environments and qualitatively detects IgM and IgG specific to SARS-CoV-2 in serum, plasma, and whole blood.
The benefit of having a SARS-CoV-2 antibody test available
Antibody tests are crucial for patient contact tracing, defining previous exposure, and for epidemiological studies. Epidemiological studies are urgently needed to help uncover the spread and burden of disease, in particular, the rate of asymptomatic infections, and to get better estimates on morbidity and mortality. This test may also be used together with molecular tests, like Roche’s cobas® SARS-CoV-2 PCR test, to aid in the diagnosis of suspected COVID-19 patients. As more is understood about immunity to SARS-CoV-2, it may help to assess who has built up immunity to the virus helping healthcare providers better manage patients.
Put the answer in your hands. When lab testing isn’t available, quality is imperative and time is of the essence, the Roche SARS-CoV-2 Rapid Antibody Test will provide healthcare professionals with the tool they need to give patients fast answers. One finger prick is all it takes.
Features and benefits of the SARS-CoV-2 Rapid Antibody Test
The SARS-CoV-2 Rapid Antibody Test can help relieve the burden on healthcare infrastructure generally by making reliable accurate testing possible in decentralised locations, complementing laboratory diagnostics and enabling effective screening. This allows for widespread mass screening without the need to over-burden specialist staff and laboratories. Patients can get a quick and convenient answer that in combination with local and national policies will help them modify their behaviour and help contain the virus and optimise restriction strategies. Follow-up appointments between patients and doctors to discuss the test results can be avoided.
One of the key benefits of the SARS-CoV-2 Rapid Antibody Test is that it can be performed with a small capillary blood sample (20 μl) from the fingertip. It opens the door to testing even for elderly and infirm individuals for whom a venous blood draw is not viable or convenient. And because this rapid test delivers reliable results, clinicians can trust on the results and advise patients with confidence43.
The benefits of the SARS-CoV-2 Rapid Antibody Test in short:
- Getting a quick result (10-15 minutes) – no need for follow-ups to discuss test results
- Easy handling which does not require specific training
- Only needing a very small capillary sample of 20ul
- Access to testing in areas where laboratory testing is not available, or when a venous blood draw is not suitable.